STOCK TITAN

PACS Group (NYSE: PACS) raises 2026 guidance on strong Q2 earnings surge

(High)
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

PACS Group, Inc. reported strong second quarter 2026 results, with revenue of $1.43 billion, up 9.1% year over year. Net income was $76.3 million, an increase of 49.8%, and diluted EPS was $0.47, up 51.6%. Adjusted EPS was $0.63, up 34.0%, Adjusted EBITDA was $166.8 million, up 24.6%, and Adjusted EBITDAR reached $261.5 million.

Same‑store skilled nursing revenue grew 5.8%, with occupancy rising to 90.6% from 89.1%. Overall occupancy was 90.4% versus an industry average of 79.5%, and skilled mix increased to 30.0%. Cash provided by operating activities was $371.8 million for the first half of 2026, and available liquidity was $756.6 million, including $164.5 million of cash and cash equivalents.

The company is expanding through the previously announced Eduro Healthcare transaction for 34 skilled nursing facilities totaling 3,633 beds, having closed on 20 Texas facilities as of August 1, 2026. PACS raised its 2026 guidance, lifting Adjusted EBITDA to $640–$660 million and revenue to $5.75–$5.85 billion, reflecting contributions from the closed Eduro Texas facilities.

Positive

  • Q2 profitability expanded sharply, with net income rising 49.8% to $76.3 million and diluted EPS increasing 51.6% to $0.47, supported by 24.6% growth in Adjusted EBITDA to $166.8 million.
  • 2026 outlook was raised, with Adjusted EBITDA guidance increased to $640–$660 million from $605–$625 million and revenue guidance lifted to $5.75–$5.85 billion from $5.65–$5.75 billion.
  • Operational metrics and liquidity are strong, including overall occupancy of 90.4% versus a 79.5% industry average, operating cash flow of $371.8 million for the first half of 2026, and total liquidity of $756.6 million.

Negative

  • None.

Filing Explained

As of June 30, 2026, cash, cash equivalents and restricted cash had decreased by $55,138 thousand during the first half.

This Form 8-K reports that the acquisition remains partly completed: 20 of the 22 Texas operations closed on August 1, 2026, while the other 14 Eduro facilities are expected to close in the third and fourth quarters of 2026.

The revised 2026 outlook includes a modest contribution from the 20 closed Texas facilities, but excludes the remaining Eduro facilities and any future acquisitions; the full 34-facility transaction therefore is not yet reflected in that outlook.

For the six months ended June 30, 2026, operating activities provided $371,842 thousand, while investing and financing activities used $282,699 thousand and $144,281 thousand; cash, cash equivalents and restricted cash decreased by $55,138 thousand.

Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Revenue Q2 2026 $1.43 billion Three months ended June 30, 2026; 9.1% increase over prior year.
Net income Q2 2026 $76.3 million Increase of $25.4 million, or 49.8%, from $51.0 million in prior-year period.
Diluted EPS Q2 2026 $0.47 Diluted earnings per share; increase of 51.6% over prior year.
Adjusted EBITDA Q2 2026 $166.8 million Adjusted EBITDA for the quarter; up $32.9 million, or 24.6%, from $133.9 million.
Cash from operations H1 2026 $371.8 million Cash provided by operating activities for the six months ended June 30, 2026.
Available liquidity 6/30/2026 $756.6 million Liquidity as of June 30, 2026, including $164.5 million of cash and cash equivalents.
2026 Adjusted EBITDA guidance $640 million to $660 million Full-year 2026 Adjusted EBITDA guidance range; raised from $605 million to $625 million.
2026 revenue guidance $5.75 billion to $5.85 billion Full-year 2026 revenue guidance range; raised from $5.65 billion to $5.75 billion.
Adjusted EBITDA financial
"We increased revenue by more than 9%, grew Adjusted EBITDA 25%, and generated strong operating cash flow"
Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.
Adjusted EBITDAR financial
"Adjusted EBITDAR was $261.5 million."
Adjusted EBITDAR is a company’s reported profit measure that starts with operating earnings and then adds back interest, taxes, depreciation, amortization and rent, plus any one‑time items companies exclude. It aims to show how much cash a business generates from its core operations before the costs of financing, non‑cash accounting charges and property leases, like comparing two stores’ underlying sales by ignoring rent and loan payments. Investors use it to compare operating performance across firms and assess ability to cover fixed obligations, but companies may calculate it differently, so comparisons require caution.
skilled mix financial
"skilled mix increased in both revenue and nursing patient days."
same-store basis financial
"On a same-store basis, which includes the 284 skilled nursing facilities"
A measure of revenue or sales growth that compares performance only for locations or operations that were open in both the current and prior reporting periods, excluding new or closed outlets. It matters to investors because it isolates organic, like-for-like performance from gains driven by opening or buying new locations, giving a clearer view of whether the core business is improving—like comparing how the same set of stores did this year versus last year.
Non-GAAP Financial Measures financial
"Adjusted Earnings Per Share, Adjusted EBITDA, and Adjusted EBITDAR are Non-GAAP Financial Measures."
Non-GAAP financial measures are numbers companies use to show their financial performance that exclude certain expenses or income. They help investors see how the company might perform without one-time costs or other unusual items, giving a different perspective from official reports. However, since they can be adjusted, they don’t always tell the full story and should be looked at alongside standard financial figures.
Revenue Q2 2026 $1.43 billion Increase of 9.1% over the prior-year period.
Net income Q2 2026 $76.3 million Increase of $25.4 million, or 49.8%, from $51.0 million in the prior-year period.
Diluted EPS Q2 2026 $0.47 Increase of 51.6% over the prior year.
Adjusted EBITDA Q2 2026 $166.8 million Increase of $32.9 million, or 24.6%, from $133.9 million in the prior-year period.
Cash from operations H1 2026 $371.8 million Compared with $202.8 million of cash provided by operating activities in the prior-year period.
Guidance

For full-year 2026, PACS raised Adjusted EBITDA guidance to $640 million to $660 million from $605 million to $625 million and increased revenue guidance to $5.75 billion to $5.85 billion from $5.65 billion to $5.75 billion, reflecting a modest contribution from the 20 Eduro Texas facilities closed on August 1, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

How did PACS (PACS) perform financially in the second quarter of 2026?

PACS Group reported Q2 2026 revenue of $1.43 billion, up 9.1% year over year, and net income of $76.3 million, up 49.8%. The company also delivered Adjusted EBITDA of $166.8 million, reflecting 24.6% growth versus the prior-year quarter.

What were PACS (PACS) earnings per share for Q2 2026, both GAAP and adjusted?

For Q2 2026, PACS reported diluted EPS of $0.47, an increase of 51.6% over the prior year. Adjusted Earnings Per Share were $0.63, up 34.0%, reflecting adjustments for acquisition-related costs, stock-based compensation, and legal and other costs, net of tax.

What 2026 guidance did PACS (PACS) provide for revenue and Adjusted EBITDA?

PACS increased its full-year 2026 guidance, targeting Adjusted EBITDA of $640–$660 million versus prior guidance of $605–$625 million. It also raised revenue guidance to $5.75–$5.85 billion, up from $5.65–$5.75 billion, incorporating a modest contribution from 20 Eduro Texas facilities.

How strong are PACS (PACS) occupancy and quality metrics in Q2 2026?

In Q2 2026, PACS achieved overall occupancy of 90.4%, compared with an industry average of 79.5%. On a same-store basis, skilled nursing occupancy was 90.6%, and 83.6% of skilled nursing facilities earned a 4 or 5 star CMS Quality Measure rating.

What is the status of PACS (PACS) Eduro Healthcare acquisition?

PACS subsidiaries agreed to acquire operations of 34 skilled nursing facilities from Eduro Healthcare, totaling 3,633 beds. As of August 1, 2026, PACS had closed on 20 of 22 Texas facilities, with the remaining 14 Eduro facilities expected to close in the third and fourth quarters of 2026.

What were PACS (PACS) cash flow and liquidity levels as of June 30, 2026?

For the six months ended June 30, 2026, PACS generated cash from operating activities of $371.8 million. As of June 30, 2026, available liquidity totaled $756.6 million, including $164.5 million of cash and cash equivalents, supporting ongoing growth and investment plans.

How is PACS (PACS) investing in growth and real estate in 2026?

During Q2 2026, PACS deployed $104.3 million to acquire real estate, bringing year-to-date real estate investment to $190.8 million. These investments complement the Eduro facility acquisition and support the company’s strategy of expanding its post‑acute care footprint and owned real estate base.
false000200118400020011842026-08-042026-08-04

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 4, 2026
PACS GROUP, INC.
(Exact name of registrant as specified in its charter)
Delaware001-4201192-3144268
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification Number)
90 S. 400 W. Suite 700
Salt Lake City, Utah 84101
(Address of principal executive offices, including Zip Code)
Registrant’s telephone number, including area code: (801) 447-9829
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading
Symbol(s)
Name of each exchange
on which registered
Common Stock, $0.001 par value per sharePACSThe New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o



Item 2.02. Results of Operations and Financial Condition.
On August 4, 2026, PACS Group, Inc. (the “Company”) issued a press release announcing financial results for its second quarter ended June 30, 2026. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information contained in this Current Report on Form 8-K (including Exhibit 99.1 hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
Exhibit No.Description
99.1
Press Release of the Company dated August 4, 2026
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
PACS GROUP, INC.
Date: August 4, 2026
By:/s/ Carey Hendrickson
Carey Hendrickson
Chief Financial Officer




PACS Group, Inc. Reports Second Quarter 2026 Results

Conference Call and Webcast Scheduled for Tomorrow, August 5, 2026, at 11:30 am ET.

SALT LAKE CITY, Utah, August 4, 2026 – PACS Group, Inc. (NYSE: PACS) (“PACS” or the “Company”), which together with its subsidiaries is one of the largest post-acute healthcare companies in the United States, announced operating results for the second quarter of 2026.
Second Quarter 2026 Financial Highlights

Revenue was $1.43 billion, an increase of 9.1% over prior year.
Net income was $76.3 million, an increase of $25.4 million, or 49.8% from $51.0 million in the prior-year period.
Diluted Earnings Per Share was $0.47, an increase of 51.6% over prior year, and Adjusted Earnings Per Share was $0.63, an increase of 34.0% over prior year.1
Adjusted EBITDA was $166.8 million, an increase of $32.9 million, or 24.6% from $133.9 million in the prior-year period.1
Adjusted EBITDAR was $261.5 million.1

Second Quarter 2026 Select KPIs

On a same-store basis, which includes the 284 skilled nursing facilities (“SNFs”) operated by the Company as of the beginning of 2025, SNF revenue increased 5.8% in the second quarter of 2026 compared to the prior-year period. Occupancy improved to 90.6% from 89.1% in the second quarter of 2025, and skilled mix increased in both revenue and nursing patient days.
The Company had 239 facilities, or 83.6%, of its skilled nursing portfolio achieve a 4 or 5 star CMS Quality Measure Star rating, with its 184 mature facilities achieving an average rating of 4.5.
Overall occupancy was 90.4%, compared to an industry average of 79.5%. Mature facilities occupancy was 93.8%.
Mature facilities skilled mix was 31.9%, while overall skilled mix increased to 30.0%, an improvement of 100 basis points from 29.0% in the prior-year period, driven by continued improvement in our Ramping facilities cohort.
Cash provided by operating activities was $371.8 million for the six months ended June 30, 2026.
The Company deployed $104.3 million to acquire real estate during the second quarter of 2026, bringing the total real estate investment to $190.8 million for the first six months of the year.
As of June 30, 2026, the Company had $756.6 million in available liquidity, including $164.5 million of cash and cash equivalents.

“Our second quarter results reflect the continued strength of the PACS platform and the exceptional execution of our local leadership teams across the country. We delivered strong growth in revenue, net income, occupancy and skilled mix while continuing to improve quality outcomes throughout our portfolio,” said Jason Murray, PACS Chief Executive Officer. “Just as important, we are expanding our footprint through acquisitions, including the Eduro transaction previously announced, which will add 34 well-positioned facilities in Texas and other attractive markets. We believe these additions, combined with our proven operating model and deep bench of experienced leaders, create meaningful opportunities to enhance care, support our facility teams and drive long-term growth. As we enter the second half of the year, we remain confident in the momentum of our business and our ability to create value through both operational excellence and disciplined expansion.”

“Our second quarter results highlight the effectiveness of our operating model in driving continued improvement across both our mature and ramping cohorts. We increased revenue by more than 9%, grew Adjusted EBITDA 25%, and generated strong operating cash flow while maintaining substantial liquidity and a conservative balance sheet,” said Carey Hendrickson, PACS Chief Financial Officer. “At the same time, we continue to invest in long-term growth through strategic real estate acquisitions and the integration of additional facilities. Our strong operating performance provides us
1 Adjusted Earnings Per Share, Adjusted EBITDA, and Adjusted EBITDAR are Non-GAAP Financial Measures. See “Reconciliation of GAAP to Non-GAAP Financial Information”.
1


the flexibility to pursue growth opportunities from a position of financial discipline, and we are well positioned to continue scaling the PACS platform and delivering meaningful value for stakeholders.”

Growth Highlights
As previously announced on June 29, 2026, subsidiaries of PACS have entered into a definitive agreement to acquire the operations of 34 skilled nursing facilities across six western states from Eduro Healthcare. The operations are in Texas (22 facilities), Montana (six facilities), South Dakota (three facilities), and one facility in each of New Mexico, North Dakota, and Utah. Collectively, the facilities comprise 3,633 skilled nursing beds. As of August 1, 2026, PACS has closed on its acquisition of the operations of 20 of the 22 Texas facilities, with the remaining 14 Eduro facilities expected to close in the third and fourth quarters of 2026.

Revised 2026 Business Outlook

“Given the continued excellent performance of our portfolio across all cohorts, we are increasing our full-year 2026 Adjusted EBITDA guidance to a range of $640 million to $660 million, up from our prior range of $605 million to $625 million,” said Hendrickson. “At the midpoint, this represents approximately 29% growth over 2025.”

“We are also increasing our revenue guidance to $5.75 billion to $5.85 billion, up from our prior range of $5.65 billion to $5.75 billion."

"Our guidance reflects a modest contribution of anticipated revenue and EBITDA related to the 20 Texas facilities associated with the Eduro transaction that closed on August 1, 2026. It does not include the remaining Eduro facilities that have yet to close, nor does it include any future acquisitions. That said, we continue to see a robust pipeline of acquisition opportunities and remain actively engaged in evaluating potential transactions that align with our strategic, operational and financial criteria,” said Hendrickson.

As of today, PACS's growing portfolio comprises 344 healthcare operations across 17 states. PACS owns 64 facilities and leases an additional 49 facilities with partial ownership in real estate. PACS holds 36 purchase options on leased facilities and 20 purchase options through partnerships. The Company remains focused on acquiring underperforming and moderately performing operations where its operating model can drive meaningful improvement, while selectively investing in real estate to support long-term value creation.
A live webcast will be held August 5, 2026, at 11:30 a.m. Eastern time to discuss PACS’s second quarter financial results. To listen to the webcast please visit the Investor Relations section of PACS’s website at https://IR.pacs.com or by dialing 877-407-0621 / +1 215-268-9899. The webcast will be recorded and will be available for replay via the website for 30 days following the call.
About PACS™
PACS Group, Inc. is a holding company investing in post-acute healthcare facilities, professionals, and ancillary services. Founded in 2013, PACS Group is one of the largest post-acute platforms in the United States. Its independent subsidiaries operate 344 post-acute care facilities across 17 states serving over 33,400 patients daily. References herein to the consolidated “Company,” as well as the use of the terms “we,” “us,” “our,” “its” and similar verbiage, refer to PACS Group, Inc. and its consolidated subsidiaries, taken as a whole. PACS Group, Inc. and its subsidiaries that are not licensed healthcare providers do not provide healthcare services to patients, residents or any other person, and do not direct or control the provision of services provided or the operations of those provider subsidiaries. All healthcare services are provided solely by its applicable subsidiaries that are licensed healthcare providers, under the direction and control of licensed healthcare professionals in accordance with applicable law. More information about PACS is available at https://IR.pacs.com. The information on our website is not part of this press release.
2


Investors: IR@pacs.com

Media: Brooks Stevenson
VP Corporate Communication
90 S. 400 W. Suite 700
Salt Lake City, UT 84101
T: 385-988-3596
brooks.stevenson@pacs.com
https://www.pacs.com
https://ir.pacs.com
Forward Looking Statements Disclaimer
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release other than statements of historical fact, including statements regarding our future financial performance and guidance, including expected revenue and adjusted EBITDA for fiscal year 2026, business strategy and growth plans, acquisition and integration activities, including the expected timing of remaining facility closings, operational and quality improvement initiatives, capital allocation and investment strategies, expectations regarding our acquisition pipeline and future transactions, uncertainty regarding the timing, amount, and continuation of payments under California's WQIP or similar state programs; our ability to execute share repurchases at favorable prices or at all, and the impact of repurchases on our capital position and liquidity; and other expectations, beliefs, plans, or objectives of management, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “shall,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” “goal,” “objective,” “seeks,” or “continue,” or the negative of these terms or other similar expressions. Forward-looking statements are neither promises nor guarantees and are based on management’s current expectations, estimates, forecasts and assumptions and on trends that we believe may affect our business, results of operations, financial condition and prospects. These statements are subject to risks, uncertainties and other important factors that may cause actual results to differ materially from those expressed or implied by the forward-looking statements, including, without limitation, our dependence on reimbursement from third-party payors, and changes in patient acuity mix, payor mix, payment methodologies, or new cost-containment initiatives could negatively impact our revenue and results of operations; we may not be fully reimbursed for all services billed through consolidated billing or bundled payments, reducing our revenue and financial condition; increased competition for, or shortages of, nurses, nurse assistants and other skilled personnel could raise labor costs and subject us to monetary fines; state efforts to regulate or deregulate healthcare services or the construction, expansion, or acquisition of healthcare facilities could impair our ability to expand or increase competition; failure to attract patients and residents or compete effectively with other healthcare providers may reduce our revenue and profitability; reviews and audits of care delivery, recordkeeping and billing may detect noncompliance requiring repayment of billed amounts or other costs; litigation and claims common in our industry could result in significant legal costs, settlements or damage awards, and our self-insurance programs may expose us to unexpected costs and losses; material weaknesses in our internal control over financial reporting, or failure to remediate such weaknesses or maintain effective controls, could impair timely and accurate reporting, reduce investor confidence, subject us to penalties, and affect the value of our common stock; inability to provide consistently high quality of care, or employee conduct that impacts patient health, safety or clinical treatment, could result in civil or criminal penalties and harm our operations; significant reliance on information technology, and any failure or interruption of that technology, could impair our operations; operational metrics derived from internal systems without independent verification may contain inaccuracies that harm our reputation; inability to complete acquisitions at attractive prices or at all may reduce revenue, and divestitures of underperforming or non-strategic subsidiaries would further decrease revenue; we may not successfully integrate acquired facilities or achieve expected benefits; acquisitions may entail unforeseen costs, liabilities or regulatory issues that adversely affect our operations; difficulty completing partnerships consistent with our growth strategy; failure to achieve or maintain competitive quality ratings from CMS or private rating organizations could negatively affect us; inability to obtain insurance or increases in insurance costs could impair our financial condition; geographic concentration of our facilities, including in California, increases vulnerability to local economic downturns, regulatory changes or natural disasters; actions of national labor unions may reduce our revenue and profitability; because we lease most facilities, we face risks from lease termination, extensions and special charges that could affect our financial condition and results of operations; insufficient cash flow to cover required payments or meet
3


covenants under long-term debt, mortgages and leases could trigger defaults and cross-defaults, risking loss of facilities or foreclosures; we may need additional capital to fund operations and growth, which may be unavailable or available only on unfavorable terms; extensive and complex laws and regulations govern our industry, and noncompliance or regulatory changes could require significant expenditures or operational modifications; our founders, Jason Murray and Mark Hancock, hold substantial control and a substantial portion of our outstanding common stock, and their interests may conflict with those of other stockholders; as a "controlled company" under NYSE governance standards, we may rely on exemptions from certain requirements, and stockholders may not have the same protections afforded to stockholders of non-controlled companies. These and other important factors are described under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, and in other filings that we make with the Securities and Exchange Commission from time to time. Any forward-looking statements contained in this press release speak only as of the date hereof. We undertake no obligation to update any forward-looking statements contained herein to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.
4


PACS GROUP, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(dollars in thousands, except for share and per share values)
Unaudited
June 30,December 31,
20262025
ASSETS
Current Assets:
Cash and cash equivalents$164,451 $197,016 
Accounts receivable, net634,496 628,128 
Other receivables89,413 73,965 
Prepaid expenses and other current assets73,994 170,630 
Total Current Assets962,354 1,069,739 
Property and equipment, net1,397,436 1,201,096 
Operating lease right-of-use assets2,862,741 2,968,176 
Insurance subsidiary deposits and investments134,721 87,192 
Escrow funds21,726 18,404 
Goodwill and other indefinite-lived assets68,061 68,061 
Other assets209,282 171,366 
Total Assets$5,656,321 $5,584,034 
LIABILITIES AND EQUITY
Current Liabilities:
Accounts payable$160,880 $192,232 
Accrued payroll and benefits187,689 187,516 
Current operating lease liabilities156,062 153,066 
Current maturities of long-term debt7,380 4,463 
Current portion of accrued self-insurance liabilities157,107 128,994 
Refund liability181,129 181,129 
Other accrued expenses204,811 154,030 
Total Current Liabilities1,055,058 1,001,430 
Long-term operating lease liabilities2,848,918 2,939,854 
Line of credit— 100,000 
Long-term debt, less current maturities, net of deferred financing fees238,709 244,803 
Accrued self-insurance liabilities, less current portion237,774 192,561 
Other liabilities160,462 152,937 
Total Liabilities$4,540,921 $4,631,585 
Commitments and contingencies
Equity:
PACS Group, Inc. stockholders' equity:
Common stock: $0.001 par value; 1,250,000,000 shares authorized; 158,335,612 shares issued and outstanding as of June 30, 2026, and 156,615,144 shares issued and outstanding as of December 31, 2025
158 157 
Additional paid-in capital643,598 637,035 
Retained earnings466,644 309,579 
Total PACS Group, Inc. stockholders' equity1,110,400 946,771 
Noncontrolling interest in subsidiary5,000 5,678 
Total Equity$1,115,400 $952,449 
Total Liabilities and Equity$5,656,321 $5,584,034 
5


PACS GROUP, INC. AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(dollars in thousands, except for share and per share values)
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Revenue
Patient and resident service revenue$1,427,497 $1,308,881 $2,847,456 $2,585,866 
Other revenues501 355 1,036 520 
Total Revenue $1,427,998 $1,309,236 $2,848,492 $2,586,386 
Operating Expenses
Cost of services1,089,538 1,020,879 2,164,074 2,044,670 
Rent - cost of services94,700 94,348 190,231 188,143 
General and administrative expense114,308 100,332 226,623 199,051 
Depreciation and amortization20,121 13,178 38,198 25,883 
Total Operating Expenses $1,318,667 $1,228,737 $2,619,126 $2,457,747 
Operating income109,331 80,499 229,366 128,639 
Other (Expense) Income
Interest expense(6,042)(4,354)(12,466)(11,258)
Other income, net2,548 2,467 2,673 3,961 
Total Other Expense, Net $(3,494)$(1,887)$(9,793)$(7,297)
Income before provision for income taxes105,837 78,612 219,573 121,342 
Provision for income taxes29,488 27,646 62,556 41,996 
Net Income$76,349 $50,966 $157,017 $79,346 
Less:
Net (loss) income attributable to noncontrolling interest(21)(48)(89)
Net Income Attributable To PACS Group, Inc.$76,370 $50,963 $157,065 $79,435 
Net Income Per Share Attributable To PACS Group, Inc.
Basic$0.48 $0.33 $1.00 $0.51 
Diluted$0.47 $0.31 $0.97 $0.48 
Weighted-Average Common Shares Outstanding
Basic158,113,224 156,335,230 157,596,175 155,759,569 
Diluted161,986,725 165,474,133 162,013,611 165,942,274 


6


PACS GROUP, INC. AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(dollars in thousands)
The following table presents selected data from our condensed consolidated statements of cash flows for the periods presented:
Six Months Ended June 30,
20262025
Net cash provided by/(used in):
Operating activities$371,842 $202,818 
Investing activities(282,699)(48,821)
Financing activities(144,281)(17,197)
Net change in cash(55,138)136,800 
Cash, cash equivalents, and restricted cash - beginning of period232,051 160,842 
Cash, cash equivalents, and restricted cash - end of period$176,913 $297,642 


7


PACS GROUP, INC. AND SUBSIDIARIES
UNAUDITED KEY SKILLED SERVICES METRICS


We categorize our facilities into three cohorts. Mature facilities are defined as facilities purchased more than 36 months prior to a respective measurement date. Ramping facilities are defined as facilities purchased within 18 to 36 months prior to a respective measurement date. New facilities are defined as facilities purchased or built less than 18 months prior to a respective measurement date.
The following tables present key skilled services metrics by category for the skilled nursing facilities in each of the three facility cohorts, and for all skilled nursing facilities as of and for the three and six months ended June 30, 2026 and 2025:
Three Months Ended June 30, 2026
MatureRampingNewTotal
(Dollars in thousands)
Skilled nursing services revenue (1)
$911,967 $370,863 $93,417 $1,376,247 
Skilled mix by revenue (2)
54.0 %42.0 %44.3 %50.0 %
Skilled mix by nursing patient days (3)
31.9 %26.9 %27.2 %30.0 %
Occupancy for skilled nursing services:
Available patient days1,798,861 875,953 309,076 2,983,890 
Actual patient days1,686,576 767,951 243,111 2,697,638 
Occupancy rate (operational beds) (4)
93.8 %87.7 %78.7 %90.4 %
Number of facilities at period end184 100 290 
Number of operational beds at period end20,612 11,403 775 32,790 

Three Months Ended June 30, 2025
MatureRampingNewTotal
(Dollars in thousands)
Skilled nursing services revenue (1)
$709,432 $278,503 $290,210 $1,278,145 
Skilled mix by revenue (2)
56.9 %41.3 %38.9 %49.4 %
Skilled mix by nursing patient days (3)
34.2 %22.5 %24.8 %29.0 %
Occupancy for skilled nursing services:
Available patient days1,393,773 709,601 827,554 2,930,928 
Actual patient days1,319,679 611,000 666,420 2,597,099 
Occupancy rate (operational beds) (4)
94.7 %86.1 %80.5 %88.6 %
Number of facilities at period end141 61 85 287 
Number of operational beds at period end15,363 7,751 9,094 32,208 
Six Months Ended June 30, 2026
MatureRampingNewTotal
(Dollars in thousands)
Skilled nursing services revenue (1)
$1,747,021 $700,877 $306,791 $2,754,689 
Skilled mix by revenue (2)
54.7 %44.2 %40.4 %50.3 %
Skilled mix by nursing patient days (3)
32.4 %27.3 %26.7 %30.3 %
Occupancy for skilled nursing services:
Available patient days3,394,154 1,628,322 909,544 5,932,020 
Actual patient days3,198,905 1,436,550 739,607 5,375,062 
Occupancy rate (operational beds) (4)
94.2 %88.2 %81.3 %90.6 %
Number of facilities at period end184 100 290 
Number of operational beds at period end20,612 11,403 775 32,790 

8


Six Months Ended June 30, 2025
MatureRampingNewTotal
(Dollars in thousands)
Skilled nursing services revenue (1)
$1,401,592 $525,273 $605,355 $2,532,220 
Skilled mix by revenue (2)
56.9 %42.6 %39.4 %49.7 %
Skilled mix by nursing patient days (3)
34.1 %23.3 %25.2 %29.3 %
Occupancy for skilled nursing services:
Available patient days2,756,999 1,321,926 1,750,484 5,829,409 
Actual patient days2,621,386 1,140,172 1,421,260 5,182,818 
Occupancy rate (operational beds) (4)
95.1 %86.3 %81.2 %88.9 %
Number of facilities at period end141 61 85 287 
Number of operational beds at period end15,363 7,751 9,094 32,208 
__________________
(1)Portion of patient and resident service revenue generated from all patients in skilled nursing facilities.
(2)Portion of routine revenue generated from treating high acuity Medicare and managed care patients.
(3)Number of days that high acuity Medicare and managed care patients receive skilled nursing services at skilled nursing facilities as a percentage of the total number of days that patients from all payor sources receive skilled nursing services at skilled nursing facilities.
(4)Total number of patients occupying a bed in a skilled nursing facility as a percentage of the beds in such facility that are available for occupancy.

9


The following tables present additional detail regarding our skilled mix, including our percentage of revenue and nursing patient days by payor source for the skilled nursing facilities in each of the three facility cohorts, and for all skilled nursing facilities, for the three and six months ended June 30, 2026 and 2025:

Skilled mix by revenue:
Three Months Ended June 30, 2026
MatureRampingNewTotal
Medicare38.3 %25.9 %25.2 %33.9 %
Managed care15.7 16.1 19.1 16.1 
Skilled mix54.0 42.0 44.3 50.0 
Medicaid36.7 47.7 45.9 40.4 
Private and other9.3 10.3 9.8 9.6 
Total100.0 %100.0 %100.0 %100.0 %
Three Months Ended June 30, 2025
MatureRampingNewTotal
Medicare41.9 %29.9 %22.2 %34.8 %
Managed care15.0 11.4 16.7 14.6 
Skilled mix56.9 41.3 38.9 49.4 
Medicaid34.5 48.8 51.4 41.5 
Private and other8.6 9.9 9.7 9.1 
Total100.0 %100.0 %100.0 %100.0 %
Six Months Ended June 30, 2026
MatureRampingNewTotal
Medicare39.0 %28.7 %21.7 %34.3 %
Managed care15.7 15.5 18.7 16.0 
Skilled mix54.7 44.2 40.4 50.3 
Medicaid36.3 45.8 49.0 40.2 
Private and other9.0 10.0 10.6 9.5 
Total100.0 %100.0 %100.0 %100.0 %
Six Months Ended June 30, 2025
MatureRampingNewTotal
Medicare41.6 %31.2 %21.6 %34.6 %
Managed care15.3 11.4 17.8 15.1 
Skilled mix56.9 42.6 39.4 49.7 
Medicaid34.7 48.1 51.1 41.4 
Private and other8.4 9.3 9.5 8.9 
Total100.0 %100.0 %100.0 %100.0 %
10


Skilled mix by nursing patient days:
Three Months Ended June 30, 2026
MatureRampingNewTotal
Medicare20.2 %14.5 %13.5 %18.0 %
Managed care11.7 12.4 13.7 12.0 
Skilled mix31.9 26.9 27.2 30.0 
Medicaid58.6 61.5 60.2 59.6 
Private and other9.5 11.6 12.6 10.4 
Total100.0 %100.0 %100.0 %100.0 %
Three Months Ended June 30, 2025
MatureRampingNewTotal
Medicare22.6 %14.0 %12.1 %17.8 %
Managed care11.6 8.5 12.7 11.2 
Skilled mix34.2 22.5 24.8 29.0 
Medicaid56.6 66.8 63.9 60.9 
Private and other9.2 10.7 11.3 10.1 
Total100.0 %100.0 %100.0 %100.0 %
Six Months Ended June 30, 2026
MatureRampingNewTotal
Medicare20.7 %15.4 %12.5 %18.2 %
Managed care11.7 11.9 14.2 12.1 
Skilled mix32.4 27.3 26.7 30.3 
Medicaid58.2 61.4 60.5 59.4 
Private and other9.4 11.3 12.8 10.3 
Total100.0 %100.0 %100.0 %100.0 %
Six Months Ended June 30, 2025
MatureRampingNewTotal
Medicare22.3 %14.7 %11.9 %17.8 %
Managed care11.8 8.6 13.3 11.5 
Skilled mix34.1 23.3 25.2 29.3 
Medicaid56.9 66.7 64.0 61.0 
Private and other9.0 10.0 10.8 9.7 
Total100.0 %100.0 %100.0 %100.0 %

11


The following tables present average daily rates by payor source, excluding services that are not covered by the daily rate, for the three and six months ended June 30, 2026 and 2025:
Three Months Ended June 30, 2026
MatureRampingNewTotal
Medicare$1,003.96 $871.30 $756.00 $956.75 
Managed care715.80 632.59 559.03 675.37 
Total for skilled patient payors (1)
898.45 761.48 656.36 843.78 
Medicaid331.65 377.78 307.13 342.98 
Private and other516.55 433.47 317.27 468.55 
Total (2)
$529.93 $487.29 $403.51 $506.40 
Three Months Ended June 30, 2025
MatureRampingNewTotal
Medicare$981.81 $969.59 $799.25 $947.67 
Managed care682.49 601.06 579.79 637.91 
Total for skilled patient payors (1)
880.26 829.59 687.39 828.71 
Medicaid322.77 329.54 352.91 332.64 
Private and other493.00 418.50 377.19 441.22 
Total (2)
$529.15 $451.46 $438.74 $487.68 
Six Months Ended June 30, 2026
MatureRampingNewTotal
Medicare$1,000.91 $909.69 $740.67 $955.55 
Managed care714.64 631.14 566.06 668.67 
Total for skilled patient payors (1)
897.63 787.94 648.03 840.85 
Medicaid331.00 362.98 346.57 342.02 
Private and other510.97 433.63 354.61 461.95 
Total (2)
$531.47 $486.94 $428.13 $505.35 
Six Months Ended June 30, 2025
MatureRampingNewTotal
Medicare$981.78 $976.44 $785.03 $944.79 
Managed care680.80 610.56 574.01 635.38 
Total for skilled patient payors (1)
877.68 841.47 673.42 823.18 
Medicaid321.04 331.90 343.57 330.14 
Private and other490.94 429.79 378.46 442.76 
Total (2)
$526.36 $460.42 $430.47 $485.56 
__________________
(1)Represents weighted average of revenue generated by Medicare and managed care payor sources.
(2)Represents weighted average.

12


The following tables present the above key skilled services metrics by category for all skilled nursing facilities in operation on January 1, 2025, excluding divestitures since that time, as of and for the three and six months ended June 30, 2026 and 2025:
Three Months Ended June 30,
20262025ChangeChange %
Total Same-Store Facility Results(Dollars in thousands)
Skilled nursing services revenue$1,347,423 $1,273,392 $74,031 5.8 %
Skilled mix by revenue49.7 %49.5 %20 bps0.4 %
Skilled mix by nursing patient days29.7 %29.2 %50 bps1.7 %
Occupancy for skilled nursing services:
Actual patient days2,640,144 2,582,690 57,454 2.2 %
Occupancy rate (operational beds)90.6 %89.1 %150 bps1.7 %
Number of facilities at period end284 284 — — %
Six Months Ended June 30,
20262025ChangeChange %
Total Same-Store Facility Results(Dollars in thousands)
Skilled nursing services revenue$2,694,908 $2,521,441 $173,467 6.9 %
Skilled mix by revenue50.0 %49.9 %10 bps0.2 %
Skilled mix by nursing patient days29.9 %29.4 %50 bps1.7 %
Occupancy for skilled nursing services:
Actual patient days5,257,655 5,150,460 107,195 2.1 %
Occupancy rate (operational beds)90.8 %89.3 %150 bps1.7 %
Number of facilities at period end284 284 — — %
13


PACS GROUP, INC. AND SUBSIDIARIES
UNAUDITED RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION
(dollars in thousands except share and per share data)
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
(in thousands except share and per share data)
Net income$76,349 $50,966 $157,017 $79,346 
Less: Net (loss) income attributable to noncontrolling interest(21)(48)(89)
Net income attributable to PACS Group, Inc.$76,370 $50,963 $157,065 $79,435 
Adjustments:
Acquisition related costs734 72 734 209 
Stock-based compensation expense25,832 13,604 46,180 25,806 
Legal and other costs8,167 24,060 19,944 46,864 
Provision for income taxes on non-GAAP adjustments (1)
(9,378)(10,189)(18,052)(19,677)
Adjusted Net Income$101,725 $78,510 $205,871 $132,637 
Weighted-average diluted common shares outstanding161,986,725 165,474,133 162,013,611 165,942,274 
Diluted earnings per share$0.47 $0.31 $0.97 $0.48 
Adjusted Earnings Per Share$0.63 $0.47 $1.27 $0.80 
__________________
(1)Represents the Company’s combined federal and state statutory tax rate of approximately 27% for the three and six months ended June 30, 2026 and 2025.
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Net income$76,349 $50,966 $157,017 $79,346 
Less: Net (loss) income attributable to noncontrolling interest(21)(48)(89)
Net income attributable to PACS Group, Inc.$76,370 $50,963 $157,065 $79,435 
Add: Interest expense6,042 4,354 12,466 11,258 
Provision for income taxes29,488 27,646 62,556 41,996 
Depreciation and amortization20,121 13,178 38,198 25,883 
EBITDA$132,021 $96,141 $270,285 $158,572 
Adjustments to EBITDA:
Acquisition related costs734 72 734 209 
Stock-based compensation expense25,832 13,604 46,180 25,806 
Legal and other costs8,167 24,060 19,944 46,864 
Adjusted EBITDA$166,754 $133,877 $337,143 $231,451 
Rent - cost of services94,700 94,348 190,231 188,143 
Adjusted EBITDAR$261,454 $527,374 
Additional information
Non-cash rent expense (1)
$10,212 $12,437 $21,212 $25,140 
__________________
(1)Non-cash rent expense reflects the extent to which our GAAP rent expense recognized exceeded (or was less than) our cash rent payments.
Non-GAAP Financial Measures
In addition to our results provided throughout that are determined in accordance with GAAP, we also present the following non-GAAP financial measures: Adjusted Net Income, Adjusted Earnings Per Share, EBITDA, Adjusted EBITDA and Adjusted EBITDAR (collectively, Non-GAAP Financial Measures). Adjusted Net Income, Adjusted Earnings Per Share, EBITDA and Adjusted EBITDA are performance measures. Adjusted EBITDAR is a valuation measure. These Non-GAAP Financial Measures have no standardized meaning defined by GAAP, and therefore have limitations as analytical tools, and they should not be considered in isolation, or as a substitute for analysis of our results as reported in accordance with GAAP. You should review the reconciliation of net income to the Non-GAAP Financial Measures in the table above, together with our current quarter condensed consolidated financial statements and the related notes in their entirety, and
14


should not rely on any single financial measure. Additionally, other companies may define these or similar Non-GAAP Financial Measures with the same or similar names differently, and because these Non-GAAP Financial Measures are not standardized, it may not be possible to compare these financial measures to those of other companies. A reconciliation of Adjusted EBITDA guidance to Net Income on a forward-looking basis cannot be provided without unreasonable efforts, as the Company is unable to provide reconciling information with respect to provision for income taxes, interest expense, depreciation and amortization, and certain other expenses that are not representative of our underlying operating performances, all of which are adjustments to Adjusted EBITDA.

Performance Measures
We use Adjusted Net Income, Adjusted Earnings Per Share, EBITDA, and Adjusted EBITDA to facilitate internal comparisons of our historical operating performance on a more consistent basis, as well as for business planning and forecasting purposes. In addition, we believe the presentation of these measures is useful to investors, analysts and other interested parties in comparing our operating performance across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our ongoing operating performance.
Adjusted Net Income – We calculate Adjusted Net Income as net income, adjusted for net (loss) income attributable to noncontrolling interest, further adjusted for non-core business items as listed in Adjusted EBITDA, as well as the related income tax effects of these adjustments.
Adjusted Earnings Per Share – We calculate Adjusted Earnings Per Share by dividing Adjusted Net Income by the weighted‑average diluted shares outstanding for the applicable period.
EBITDA – We calculate EBITDA as net income, adjusted for net (loss) income attributable to noncontrolling interest, before: interest expense; provision for income taxes; and depreciation and amortization.
Adjusted EBITDA – We calculate Adjusted EBITDA as EBITDA further adjusted for non-core business items, which for the reported periods includes, to the extent applicable, costs incurred to acquire operations that are not capitalizable, stock-based compensation expense, legal and other costs, and certain one-time expenses that are not representative of our underlying operating performance. Costs related to acquisitions include costs related to our acquisition of operations, including related costs such as legal fees, financial and tax due diligence, consulting and escrow fees. Legal and other costs include legal and professional fees incurred associated with the Audit Committee’s independent investigation during the years ended December 31, 2025 and 2024, and with other ongoing investigations.
Valuation Measure
We use Adjusted EBITDAR as a measure to determine the value of prospective acquisitions and to assess the enterprise value of our business without regard to differences in capital structures and leasing arrangements. In addition, we believe that Adjusted EBITDAR is also a commonly used measure by investors, analysts and other interested parties to compare the enterprise value of different companies in the healthcare industry without regard to differences in capital structures and leasing arrangements, particularly for companies with operating and finance leases. For example, finance lease expenditures are recorded in depreciation and interest and are therefore removed from Adjusted EBITDA, whereas operating lease expenditures are recorded in rent expense and are therefore retained in Adjusted EBITDA. Adjusted EBITDAR is a financial valuation measure that is not specified in GAAP, and is not displayed as a performance measure as it excludes rent expense, which is a normal and recurring cash operating expense, and is therefore presented only for the current period. While we believe that Adjusted EBITDAR provides useful insight regarding our underlying operations, excluding the impact of our operating leases, we must still incur cash operating expenses related to our operating leases and rent and such expenses are necessary to operate our leased operations. As a result, Adjusted EBITDAR may understate the extent of our cash operating expenses for the respective period relative to our cash needs to operate our leased operations and business.

Adjusted EBITDAR – We calculate Adjusted EBITDAR as Adjusted EBITDA plus rent-cost of services.
15

Filing Exhibits & Attachments

4 documents